Test Price
800 AED✅ Home Collection Available
Sickle Cell Mutation Screening (Prenatal) – 800 AED – DNA Labs UAE
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9 % clinical sensitivity via allele‑specific endpoint PCR on fetal DNA. Price: 800 AED (inclusive of GST). Turnaround Time: 3–4 business days from sample receipt. Specimen Collection: Hospital Extraction Only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Post‑Test Guidance: Telephonic clinical consultation for result interpretation. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
This prenatal molecular assay delivers definitive detection of the HbS mutation before birth. Processing is performed under ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) at DNA Labs UAE, Dubai Healthcare City.
Test Overview & Methodology
The test uses allele‑specific endpoint polymerase chain reaction (PCR) to directly identify the point mutation in the beta‑globin gene responsible for sickle cell disease. DNA is extracted from fetal cells obtained through invasive sampling — amniotic fluid, chorionic villi, or cord blood — and amplified with primers that discriminate between the normal (HbA) and sickle (HbS) alleles. The method provides a definitive molecular result that guides prenatal counseling and delivery planning.
| Feature | Our Test (Endpoint PCR) | Standard Alternative (Hb Electrophoresis) |
|---|---|---|
| Diagnostic Precision | Direct mutation detection at the DNA level; sensitivity >99.9 % | Indirect protein separation; sensitivity ~95 % |
| Methodology | Allele‑specific endpoint PCR (ISO 9001:2015 compliant) | Hemoglobin electrophoresis (HPLC or gel‑based) |
| Turnaround Time | 3–4 days | 5–7 days |
Physician Insight & Safety Protocols
“As a Consultant in Medical Genetics licensed by the DHA, I confirm that allele‑specific endpoint PCR provides definitive molecular confirmation of the HbS mutation in fetal DNA extracted from invasive samples. A negative result does not entirely exclude rare beta‑globin variants; therefore, results must be interpreted alongside parental carrier screening, hematological parameters, and a detailed family history. All prenatal genetic testing should be accompanied by non‑directive genetic counseling before and after the procedure.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Procedural Advisory
Invasive prenatal sampling (amniocentesis or chorionic villus sampling) carries a procedure‑related risk of miscarriage estimated at 1 in 300 to 1 in 500. The procedure must be performed under continuous ultrasound guidance by a qualified maternal‑fetal medicine specialist. Informed written consent documenting the risks, benefits, and alternatives is mandatory before any sample collection. Fetal DNA yield and integrity are verified prior to PCR setup to guarantee result reliability.
Exclusion Criteria & Emergency Red Flags
- Active maternal infection (e.g., chorioamnionitis, untreated urinary tract infection) or febrile illness on the day of sampling.
- Known bleeding diathesis or coagulopathy that contraindicates an invasive procedure.
- Inadequate amniotic fluid volume (severe oligohydramnios) or technical barrier to safe needle access.
- Emergency Red Flags: Sudden severe abdominal pain, vaginal bleeding, leakage of amniotic fluid, maternal fever >38 °C, or signs of infection at the puncture site — proceed immediately to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What is the accuracy of this prenatal sickle cell mutation test?
Brief Answer: The endpoint PCR assay delivers 99.9 % clinical sensitivity for the HbS mutation when performed on adequate fetal DNA.
The test directly amplifies the mutated allele, eliminating the false‑positive rate seen with indirect protein methods. Confirmatory hemoglobin electrophoresis on cord blood at birth is recommended for complete trait characterization.
2. Is a doctor’s prescription mandatory for this test?
Brief Answer: A valid prescription from a licensed physician is required, except in cases of planned surgery, confirmed pregnancy, or documented travel abroad.
Our laboratory follows UAE Ministry of Health and Prevention (MOHAP) regulations. Patients who provide medical justification for surgery, pregnancy, or travel may proceed without a prescription after submitting appropriate supporting documents.
3. What sample types are accepted and how is collection performed?
Brief Answer: Amniotic fluid, chorionic villi, or cord blood are collected by an obstetrician under continuous ultrasound guidance.
Because these are invasive hospital‑only procedures, we coordinate with certified maternal‑fetal medicine specialists at accredited hospitals. Samples are transported via secure medical courier in ISO‑certified cold‑chain packaging to preserve DNA integrity.
4. How long does it take to get results?
Brief Answer: Results are reported within 3–4 business days from the time the sample reaches our laboratory.
The turnaround time includes DNA extraction, endpoint PCR amplification, gel or capillary electrophoresis analysis, and dual‑signature verification by a Consultant Medical Genetics. Urgent requests can be expedited upon medical justification.
5. What does a positive result mean for my pregnancy?
Brief Answer: A positive result indicates the fetus carries one or two copies of the HbS mutation, confirming sickle cell trait or disease.
Genetic counseling is strongly recommended to discuss the implications, recurrence risk, and available management options including prenatal care planning, partner screening, and neonatal follow‑up. Our post‑test telephonic guidance can help coordinate a referral to a genetic counselor or hematologist.
UAE Regulatory & Data Privacy Adherence
Legal & Compliance Framework
All services at DNA Labs UAE operate in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety, patient consent, and medical liability are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory is DHA‑licensed (Facility License No. 1143) and holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). Patient data is encrypted during transmission and storage, and access is restricted to authorized clinical personnel only.
Clinical & Logistical Metadata
| Test Name | Sickle Cell Mutation Screening (Prenatal) – HbS Allele‑Specific Endpoint PCR |
| Price (AED) | 800 AED |
| Turnaround Time | 3–4 business days |
| Sample Type / Matrix | Amniotic fluid, chorionic villi, or cord blood — Hospital Extraction Only. Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Allele‑specific endpoint polymerase chain reaction (PCR) with gel / capillary electrophoresis detection |
| ICD-10-CM Code | D57.1 |
| LOINC Code | 50398-7 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 — DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians